A Twenty-years' Experience in Pituitary Disease.

Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pituitary Adenoma Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Hypothalamic Diseases Hypothalamic Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Pituitary Cancer Pituitary Disease Pituitary Diseases Pituitary Neoplasms Supratentorial Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione Policlinico Gemelli IRCCS

Rome, IT, 00168, Italy

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients underwent surgery for pituitary tumors;
pathology diagnosis of pituitary tumors;
patients older then 18 years at diagnosis of pituitary tumors;
2 years follow-up;

Exclusion criteria

age lower then 18 years
follow-up shorter than 2 years

Treatment and study plan

Frequency of disease recurrence

Other

To collect data of pituitary disease recurrence

Primary outcomes

Tumor recurrence

Time frame: From enrollement to last observation at 24 months of follow-up

Frequency of tumor recurrence at 24 months of follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Francesco Doglietto, Prof

CONTACT

[email protected]

+390630155701

Sabrina Chiloiro, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

A Twenty-years' Experience in Pituitary Disease: Identification of Prognostic Factors in Pituitary Tumors

Acronym: TYEPDD

Important dates

Study start: 2025
Primary completion: 2028
Study completion: 2028
First posted: May 15, 2025
Registry last updated: May 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting